Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Novo Nordisk is working on a new obesity drug that could help ... Semaglutide, the GLP-1 drug that Novo sells under the brand ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...